Yun-Jung Choi Selected Research

seladelpar

1/2022	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
1/2022	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
10/2017	Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
1/2017	The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yun-Jung Choi Research Topics

Disease

15	Neoplasms (Cancer) 03/2018 - 08/2002
7	Ovarian Neoplasms (Ovarian Cancer) 03/2018 - 01/2015
3	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2022 - 10/2017
3	Inflammation (Inflammations) 01/2022 - 05/2005
3	Pruritus (Itching) 01/2022 - 10/2017
3	Mitochondrial Diseases (Mitochondrial Disease) 03/2018 - 01/2015
3	Gout 01/2018 - 01/2016
3	Wounds and Injuries (Trauma) 12/2016 - 01/2015
2	Rheumatoid Arthritis 01/2018 - 01/2018
2	Nausea 10/2017 - 10/2008
2	Dizziness (Lightheadedness) 10/2017 - 10/2008
2	Weight Loss (Weight Reduction) 01/2017 - 01/2015
2	Dyslipidemias (Dyslipidemia) 01/2017 - 02/2012
2	Lung Neoplasms (Lung Cancer) 02/2016 - 09/2012
2	Carcinoma (Carcinomatosis) 02/2016 - 10/2006
2	Overweight 02/2012 - 09/2011
1	Burns 02/2022
1	Disease Progression 01/2022
1	Cholestasis 01/2022
1	Fatigue 01/2022
1	Genomic Instability 01/2020
1	Infertility (Sterility) 01/2019
1	Endometritis 04/2018
1	Communicable Diseases (Infectious Diseases) 04/2018
1	Thrombosis (Thrombus) 01/2018
1	Thromboembolism 01/2018
1	Arthritis (Polyarthritis) 01/2018
1	Hemophilia A (Haemophilia) 01/2018
1	Bone Resorption 01/2018
1	Joint Diseases (Joint Disease) 01/2018
1	Dyspepsia (Indigestion) 10/2017
1	Myalgia 10/2017
1	Spasm (Spasms) 10/2017
1	Teratoma (Teratoid Tumor) 09/2017
1	Virus Diseases (Viral Diseases) 01/2017
1	Asthma (Bronchial Asthma) 01/2017
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Body Weight (Weight, Body) 01/2017
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Hyperglycemia 01/2017
1	Hyperinsulinism (Hyperinsulinemia) 01/2017
1	Insulin Resistance 01/2017
1	Myocardial Infarction 01/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017
1	Hyperuricemia 01/2017
1	Non-alcoholic Fatty Liver Disease 01/2017

Drug/Important Bio-Agent (IBA)

7	SilverIBA 04/2018 - 01/2014
4	seladelparIBA 01/2022 - 01/2017
4	Pharmaceutical PreparationsIBA 04/2018 - 10/2008
3	MicroRNAs (MicroRNA)IBA 01/2019 - 12/2016
3	Anti-Bacterial Agents (Antibiotics)IBA 04/2018 - 01/2015
3	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2018 - 01/2015
3	graphene oxideIBA 03/2018 - 01/2015
3	arhalofenateIBA 01/2018 - 01/2016
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2017 - 02/2012
3	(2- methyl- 4- (5- methyl- 2- (4- trifluoromethyl- phenyl)- 2H- (1,2,3)triazol- 4- ylmethylsulfanyl)phenoxy)acetic acidIBA 01/2017 - 09/2011
2	PPAR deltaIBA 01/2022 - 01/2017
2	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2022 - 10/2017
2	Biological ProductsIBA 01/2019 - 12/2016
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 03/2018 - 01/2015
2	Allopurinol (Remid)FDA LinkGeneric 01/2018 - 01/2016
2	Atorvastatin (Lipitor)FDA Link 01/2018 - 09/2011
2	LipidsIBA 01/2017 - 09/2011
2	Uric Acid (Urate)IBA 01/2017 - 01/2016
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017 - 01/2017
2	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 01/2015
2	Proteins (Proteins, Gene)FDA Link 02/2016 - 05/2005
2	Caspase 3 (Caspase-3)IBA 01/2015 - 08/2002
2	Annexin A5IBA 01/2015 - 04/2007
1	Bile Acids and Salts (Bile Acids)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Alkaline PhosphataseIBA 01/2022
1	Histones (Histone)IBA 01/2020
1	Lysine (L-Lysine)FDA Link 01/2020
1	PhycoerythrinIBA 03/2018
1	salinomycinIBA 03/2018
1	Tumor Necrosis Factor InhibitorsIBA 01/2018
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2018
1	LigandsIBA 01/2018
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2018
1	Macrophage Colony-Stimulating FactorIBA 01/2018
1	CD40 Ligand (CD40L)IBA 01/2018
1	Factor VIII (Coagulation Factor VIII)IBA 01/2018
1	EpitopesIBA 01/2018
1	PerforinIBA 09/2017
1	ceric oxide (cerium dioxide)IBA 01/2017
1	locked nucleic acidIBA 01/2017
1	tubastatin AIBA 01/2017
1	Febuxostat FDA Link 01/2017
1	Histone Deacetylase 6IBA 01/2017
1	Antineoplastic Agents (Antineoplastics)IBA 01/2017
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2017
1	Ribosomal Proteins (Ribosomal Protein)IBA 01/2017
1	PPAR alphaIBA 01/2017
1	Caspase 9IBA 01/2017
1	Ribonucleases (Ribonuclease)IBA 12/2016

Therapy/Procedure

13	Therapeutics 04/2018 - 04/2009
5	Drug Therapy (Chemotherapy) 01/2017 - 01/2015
1	Emergency Treatment 02/2022
1	Ligation 01/2018